Appendiceal cancer accounts for less than 1% of gastrointestinal cancers, yet the clinical picture varies sharply by presentation and subgroup. Abdominal pain appears in 70% of cases, but 30% to 50% are found incidentally during appendectomy and may already be advanced. Women also show higher incidence, and median age at diagnosis lands at 59 years.
Key Takeaways
- Abdominal pain is the most common symptom in 70% of cases
- Female incidence rate is 1.4 per million vs 0.9 in males
- Appendix cancer accounts for less than 1% of all gastrointestinal cancers
- 5-year survival for localized disease is 85%
- Appendectomy performed in 75% of initial surgeries
Appendix cancer is rare, but early detection and timely treatment can significantly improve outcomes.
Related reading
01 · Category
Clinical Presentation29 stats
01
Abdominal pain is the most common symptom in 70% of cases
02
30-50% of appendiceal cancers found incidentally during appendectomy
03
Pseudomyxoma peritonei presents in 25% of mucinous cases
04
Elevated CEA in 40% of appendiceal adenocarcinoma patients
05
Acute appendicitis symptoms in 20-30% at presentation
06
Bowel obstruction occurs in 15% of advanced cases
07
10% present with peritoneal carcinomatosis
08
Weight loss reported in 25% of symptomatic patients
09
CA 19-9 elevated in 50% of mucinous neoplasms
10
Hernia or mass in 5-10% at diagnosis
11
Anemia present in 15% due to occult bleeding
12
Ascites in 20% of high-grade appendiceal cancers
13
CT scan detects 90% of appendiceal masses >2cm
14
MRI useful for mucin detection in 80% of pseudomyxoma cases
15
Biopsy confirms diagnosis in 95% of cases
16
40% diagnosed at stage IV
17
Nausea/vomiting in 20% of presenting symptoms
18
Colonoscopy detects 60% of advanced lesions
19
Fatigue in 18% of patients at diagnosis
20
Elevated chromogranin A in 70% of neuroendocrine appendiceal tumors
21
Palpable mass in 8% at presentation
22
PET-CT sensitivity 85% for staging
23
Change in bowel habits 12%
24
Ultrasound detects appendiceal mass in 70%
25
Jaundice rare, <2% of cases
26
Early satiety in 10% advanced cases
27
95% of diagnoses via pathology post-surgery
28
Perforation at diagnosis 25% mucinous
29
Bloating/distention 22%
Interpretation
Clinical Presentation Interpretation
Appendix cancer is a master of disguise, often masquerading as mundane belly pain or discovered by sheer luck during unrelated surgery, only to reveal its true, advanced nature far too late in a daunting array of scans and symptoms.
02 · Category
Demographics28 stats
01
Female incidence rate is 1.4 per million vs 0.9 in males
02
Median age at diagnosis for appendiceal cancer is 59 years
03
Women comprise 55% of appendiceal neuroendocrine tumor patients
04
Appendiceal mucinous neoplasms more common in females (70%)
05
Peak incidence in women aged 50-59 at 2.5 per million
06
Non-Hispanic whites represent 80% of cases
07
Male-to-female ratio for appendiceal adenocarcinoma is 1:1.2
08
Median age for goblet cell carcinoid is 52 years
09
Blacks have lower incidence at 0.8 per million
10
60% of patients diagnosed between 50-70 years
11
Hispanics account for 10% of appendiceal cancer cases
12
Appendiceal carcinoids diagnosed at younger age (median 45)
13
Female predominance in low-grade appendiceal mucinous neoplasms (65%)
14
Asian/Pacific Islanders incidence 1.1 per million
15
25% of cases under age 40 are neuroendocrine tumors
16
Right-sided appendiceal tumors more common in elderly males
17
Median age for appendiceal adenocarcinoma is 62 years
18
Blacks comprise 8% of appendiceal cancer patients
19
Median age at diagnosis for signet-ring cell is 55
20
25% of cases have family history of GI cancers
21
Women 58% of all appendiceal cancer cases
22
Asians 5% of cases
23
15-20% diagnosed during pregnancy
24
70% of incidental findings in females under 50
25
Incidence rate ratio females:males 1.5:1
26
40% of cases in urban areas
27
Pediatric cases <1% , median age 12
28
Rural incidence lower by 15%
Interpretation
Demographics Interpretation
Statistically speaking, appendix cancer is a middle-aged, predominantly white woman's world, though it occasionally gate-crashes a pregnancy or rudely introduces itself to a surprised man in his sixties.
03 · Category
Epidemiology23 stats
01
Appendix cancer accounts for less than 1% of all gastrointestinal cancers
02
Annual incidence of appendiceal cancer in the US is approximately 1.2 per 1,000,000 people
03
Global incidence rate of appendiceal neoplasms is 0.12 cases per 100,000
04
Appendiceal cancer incidence increased by 204% from 1973 to 2013 in the US
05
Prevalence of appendiceal mucinous neoplasms is about 0.25% of appendectomies
06
In Europe, appendiceal cancer incidence is 0.97 per million population
07
Appendiceal tumors represent 0.5% of colorectal malignancies
08
US annual cases of appendiceal cancer estimated at 500-1,000
09
Incidence of neuroendocrine appendiceal tumors is 0.3 per million
10
Appendiceal adenocarcinoma incidence rose 3.2% annually from 2000-2016
11
In Japan, appendiceal cancer incidence is 0.4 per 100,000
12
Appendiceal goblet cell carcinoma comprises 14-19% of appendiceal malignancies
13
Lifetime risk of appendiceal cancer is 0.012%
14
Incidence higher in non-Hispanic whites at 1.4 per million
15
Appendiceal cancer cases doubled from 1990s to 2010s
16
Mucinous appendiceal tumors occur in 6-12% of pseudomyxoma peritonei cases
17
Annual incidence in UK is 0.6 per million
18
Appendiceal signet-ring cell carcinoma is 4-20% of appendiceal cancers
19
SEER database reports 8,812 appendiceal cancer cases from 1975-2016
20
Incidence peaks in age group 60-69 at 2.1 per 100,000
21
Incidence of appendiceal cancer in Australia is 1.0 per million
22
Appendiceal tumors in 0.7% of appendiceal specimens
23
Incidence in Canada 0.9 per million
Interpretation
Epidemiology Interpretation
To call this cancer rare feels like an understatement, as finding a case is akin to winning a reverse lottery you never wanted to play, yet its quiet creep over the decades demands our unwavering attention.
More related reading
04 · Category
Prognosis and Survival27 stats
01
5-year survival for localized disease is 85%
02
Overall 5-year survival for appendiceal cancer is 63%
03
Stage IV 5-year survival 35% for adenocarcinoma
04
Mucinous histology has 78% 5-year survival vs 45% non-mucinous
05
Neuroendocrine tumors 95% 5-year survival if localized
06
Post-HIPEC median survival 100 months for low-grade
07
Goblet cell carcinoma 5-year survival 50-70%
08
Signet-ring cell has poorest prognosis, 27% 5-year survival
09
Peritoneal index predicts survival, PCI<10 has 80% 5-yr
10
Lymph node positive disease reduces 5-yr survival to 76%
11
Median survival for untreated metastatic is 12 months
12
CC-0 cytoreduction yields 5-yr survival >80%
13
Age >65 associated with 40% lower survival odds
14
Female gender improves survival by 10-15%
15
Low-grade appendiceal mucinous neoplasm (LAMN) recurrence 20%
16
10-year survival for localized carcinoid >90%
17
High-grade neuroendocrine carcinoma 5-yr survival <20%
18
10-year overall survival 50%
19
Recurrence rate after HIPEC 30% at 5 years
20
3-year survival post-cytoreduction 75%
21
Lymphovascular invasion worsens prognosis by 25%
22
Median OS for low PCI 156 months
23
5-year survival for regional disease 75%
24
Disease-free survival after R0 resection 85%
25
20-year survival for benign LAMN >95%
26
Prognostic index for goblet cell >stage III 40% 5-yr
27
MSI-high in 15% improves immunotherapy response
Interpretation
Prognosis and Survival Interpretation
These numbers paint a clear, sobering portrait: your odds in appendix cancer depend overwhelmingly on catching it early, its specific cellular personality, and the surgical team's ability to completely evict it from the premises.
05 · Category
Treatment26 stats
01
Appendectomy performed in 75% of initial surgeries
02
Cytoreductive surgery with HIPEC in 30% of peritoneal cases
03
Right hemicolectomy recommended for tumors >2cm in 90% guidelines
04
Systemic chemotherapy used in 50% of metastatic disease
05
5-FU based regimens in 60% of adjuvant treatments
06
Lymph node dissection in 40% of goblet cell carcinomas
07
Neoadjuvant chemo in 20% of high-risk mucinous tumors
08
Radiation therapy rare, used in <5% of cases
09
Targeted therapy (anti-VEGF) in 10% of advanced cases
10
Completeness of cytoreduction (CC-0/1) achieved in 70%
11
Somatostatin analogs for 80% of functional neuroendocrine tumors
12
Oxaliplatin-based chemo in 45% of regimens
13
Watchful waiting for small (<1cm) carcinoids in 50%
14
Peritonectomy in 60% of HIPEC procedures
15
Irinotecan used in 25% of second-line therapies
16
Peptide receptor therapy in 15% of metastatic NETs
17
80% of small carcinoids (<1cm) cured by appendectomy alone
18
Bevacizumab improves PFS by 20% in trials
19
Mitomycin C used in 90% of HIPEC
20
Capecitabine monotherapy in 15% elderly patients
21
FOLFOX regimen in 55% of cases
22
10% undergo liver metastasectomy
23
Immunotherapy (pembrolizumab) in 5% MSI-high tumors
24
Hyperthermic intraperitoneal chemo improves survival 50%
25
35% receive adjuvant chemotherapy
26
65% undergo optimal debulking
Interpretation
Treatment Interpretation
Even with its toolbox of impressively specific odds—from the 80% cure rate for tiny carcinoids to the rare but decisive 5% of tumors vulnerable to immunotherapy—the fight against appendix cancer remains a meticulous and brutal arithmetic of carving, heating, poisoning, and hoping, where the best outcomes are forged from a staggering number of difficult percentages.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Catherine Wu. (2026, February 13). Appendix Cancer Statistics. Gitnux. https://gitnux.org/appendix-cancer-statistics
MLA
Catherine Wu. "Appendix Cancer Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/appendix-cancer-statistics.
Chicago
Catherine Wu. 2026. "Appendix Cancer Statistics." Gitnux. https://gitnux.org/appendix-cancer-statistics.
Sources & references
7 datasets cited across this report · attribution is report-level